A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
04/03/2022at 08:22

Novo Nordisk more than doubles 2025 obesity sales goal

Danish pharmaceutical firm Novo Nordisk has upgraded its sales predictions for its weight loss products after 78-percent growth in Q4.
Photo: Novo Nordisk / PR
by marketwire, translated by catherine brett

Novo Nordisk has more than doubled its goal for the sales of its obesity drugs, now aiming for over DKK 25bn (USD 3.7bn) in sales in 2025.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Executive Vice President for Commercial Strategy and Corporate Affairs Camilla Sylvest | Photo: Novo Nordisk / PR

    Novo expects GLP-1 products to drive diabetes business growth

    For subscribers

  • Photo: Novo Nordisk Pharmatech/PR

    Novo Nordisk's first phase III data for weekly insulin to be released in few months

    For subscribers

  • Lars Fruergaard Jørgensen, CEO of Novo Nordisk | Photo: Stine Bidstrup/ERH

    Novo Nordisk CEO: "We are very encouraged by growth momentum"

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Foto: Novo Nordisk / Pr
Pharma & biotech

Sales of Novo Nordisk's Wegovy are off to a good start in 2023

Prescriptions for the obesity treatment have been kickstarted in the first weeks of 2023, new figures show.

For subscribers

Foto: Philip Davali
Pharma & biotech

Bavarian Nordic breaks even in preliminary financial update

The vaccine maker’s mpox vaccine, Jynneos, has performed so well the last year that Bavarian can now again boast profitability. 

For subscribers

Foto: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Eli Lilly predicts possible launch of obesity drug in 2023

The US-based company hopes to launch Wegovy-competitor tirzepatide for obesity this year or early next year.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Head of Regulatory Affairs Danmark

  • Experienced Patent Counsel

  • Lead Data Architect

  • Commercial Director

  • Head of International Sales

  • Application Manager

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Sr. Director, Drug Safety Physician

  • Principal Laboratory Technologist

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

See all jobs

Jobs

  • Head of Regulatory Affairs Danmark

  • Experienced Patent Counsel

  • Lead Data Architect

  • Commercial Director

  • Head of International Sales

  • Application Manager

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Sr. Director, Drug Safety Physician

  • Principal Laboratory Technologist

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge